

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

ANNOUNCEMENT

STRATEGIC CO-OPERATION FRAMEWORK AGREEMENT

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

On 28 August 2015, Zhuhai Essex Bio-Pharmaceutical entered into the Framework Agreement with Tasly, pursuant to which Tasly and Zhuhai Essex Bio-Pharmaceutical will collaborate in the research and development, clinical tests, manufacturing, sales and marketing of recombinant protein drugs.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (“**SFO**”).

On 28 August 2015, 珠海億勝生物製藥有限公司 (Zhuhai Essex Bio-Pharmaceutical Company Limited) (“**Zhuhai Essex Bio-Pharmaceutical**”), an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (the “**Company**”, and together with its subsidiaries referred as the “**Group**”), entered into a strategic co-operation framework agreement (“**Framework Agreement**”) with 天士力製藥集團股份有限公司 (Tasly Pharmaceutical Group Co., Ltd.*) (“**Tasly**”).

Given the complementary relationship between Tasly's strengths in the research and development and manufacturing of drugs in genetically engineered mammal expression system (哺乳動物基因工程表達系統藥物) and Zhuhai Essex Bio-Pharmaceutical's strengths in the research and development and manufacturing of drugs in genetically engineered microorganism expression system (微生物基因工程表達系統藥物), both parties, after friendly negotiation, agreed to establish a win-win strategic partnership on a complementary, mutually beneficial and co-development basis to commence cooperation on the development and operation of recombinant protein drugs (重組蛋白藥物).

Pursuant to the Framework Agreement, Tasly and Zhuhai Essex Bio-Pharmaceutical will collaborate in the research and development, clinical tests, manufacturing, sales and marketing of recombinant protein drugs.

The co-operation under the Framework Agreement is valid for a period of 10 years from the date of the signing of the Framework Agreement.

The Group is principally engaged in the research and development, manufacturing and distribution of biopharmaceutical products. Tasly, listed in the Shanghai Stock Exchange (stock code: 600535), is principally engaged in the research and development, manufacturing and distribution of pharmaceutical products.

By Order of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 28 August 2015

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.

* *For identification purposes only*